In a double-blind, placebo-controlled study, 18 mg of flunisolide was administered via the CFC formulation over a three-hour period (nine times the maximum labeled daily dose) in 94 patients with acute asthma, and no clinically deleterious effects were observed.
Flunisolide EG Inhalation Aerosol is contraindicated in the following conditions:
Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.
Systemic and local corticosteroid use may result in the following:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The following table shows the adverse reactions that were reported in patients previously receiving bronchodilators and/or orally inhaled corticosteroids in two double-blind, placebo-controlled US clinical trials, in which 519 adult and pediatric patients age 4-78 years (279 males and 240 females) were treated with the Flunisolide EG Inhalation Aerosol (80 mcg to 320 mcg twice daily for 12 weeks) or placebo. The mean duration of exposure was 76.7, 78.2, 80.5, and 69.4 days for Flunisolide EG Inhalation Aerosol 80 mcg, 160 mcg, 320 mcg, and placebo, all dosed twice daily, respectively. The table includes all reactions that occurred at a rate of > 3% in any Flunisolide EG Inhalation Aerosol group. In considering these data, the increased average duration of exposure for Flunisolide EG Inhalation Aerosol patients should be taken into account, compared with placebo-treated patients.
Adverse Reactions with > 3% incidence reported in controlled clinical studies with Flunisolide EG Inhalation Aerosol (% of patients)
| ADVERSE REACTION | PLACEBO (n = 220) | Flunisolide EG Inhalation Aerosol | ||
| 80 MCG (n = 189) | 160 MCG (n = 217) | 320 MCG (n = 113) | ||
| BODY AS AWHOLE | ||||
| Headache | 12.7 | 9.0 | 13.8 | 8.8 |
| Allergic Reaction | 2.3 | 4.2 | 4.6 | 4.4 |
| Infection, Bacterial | 0.9 | 3.7 | 0.9 | 0.9 |
| DIGESTIVESYSTEM | ||||
| Vomiting | 4.1 | 4.2 | 4.6 | 0.0 |
| Dyspepsia | 1.4 | 2.1 | 3.2 | 3.5 |
| RESPIRATORY SYSTEM | ||||
| Pharyngitis | 13.2 | 17.5 | 16.6 | 16.8 |
| Rhinitis | 10.0 | 9.0 | 15.7 | 3.5 |
| Cough Increased | 7.7 | 8.5 | 5.5 | 1.8 |
| Sinusitis | 5.5 | 7.4 | 4.1 | 8.8 |
| Epistaxis | 0.9 | 3.2 | 0.9 | 0.0 |
| UROGENITAL SYSTEM | ||||
| Urinary Tract Infection | 0.5 | 1.1 | 0.9 | 3.5 |
The following other adverse reactions occurred in patients in these clinical trials using Flunisolide EG Inhalation Aerosol with an incidence of 1 to 3% and were more common in Flunisolide EG Inhalation Aerosol than in the placebo group.
Body As A Whole: abdominal pain, chest pain, infection, neck pain
Digestive System: diarrhea, gastroenteritis, nausea, oral moniliasis
Metabolic And Nutritional Disorders: edema
Musculoskeletal System: myalgia
Nervous System: dizziness, insomnia, migraine
Respiratory System: bronchitis, laryngitis, voice alteration
Skin And Appendages: erythema multiforme
Special Senses: conjunctivitis, ear pain, taste perversion
Urogenital System: dysmenorrhea, vaginitis
Long-Term Clinical TrialsTwo 52-week open label safety trials of Flunisolide EG Inhalation Aerosol were conducted in 162 asthma patients 12 to 60 years of age and in 152 asthma patients 4 to 11 years of age. The adverse reaction profile exhibited in these trials was similar to that seen in the two 12-week studies.
Adverse Reactions from Other SourcesThe following additional adverse reactions were derived from clinical trials conducted with flunisolide CFC inhalation aerosol with a frequency of ≥ 1% and not described above:
Body as a Whole: flu, decreased appetite, chills, increased appetite, weight gain, malaise, peripheral edema, sweating, weakness
Gastrointestinal System: upset stomach, heartburn, constipation, gas, abdominal fullness
Cardiovascular System: palpitations, hypertension, tachycardia
Nervous System: headache, irritability, shakiness, anxiety, depression, faintness, fatigue, hyperactivity, hypoactivity, moodiness, numbness, vertigo
Respiratory System: cold symptoms, nasal congestion, upper respiratory tract infection, chest congestion, hoarseness, runny nose, sinus congestion, sinus drainage, sinus infection, sneezing, sputum, wheezing, chest tightness, bronchospasm, dyspnea, head stuffiness, nasal irritation, pleurisy, pneumonia, sinus discomfort
Skin and Appendages: eczema, pruritus, acne, urticaria
Special Senses: loss of smell, loss of taste, ear infection, blurred vision, eye discomfort, eye infection
Hemic and Lymph: capillary fragility, enlarged lymph nodes
Mouth and Throat: sore throat, dry throat, glossitis, mouth irritation, phlegm, throat irritation
Flunisolide EG Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. Flunisolide EG Inhalation Aerosol is also indicated for asthma patients requiring oral corticosteroid therapy, where adding Flunisolide EG Inhalation Aerosol may reduce or eliminate the need for oral corticosteroids.
Important Limitations of UseFlunisolide EG Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm.
Flunisolide EG Inhalation Aerosol is NOT indicated in children less than 6 years of age.
Dose finding for Flunisolide EG Inhalation Aerosol was based on comparability of systemic exposure to flunisolide CFC inhalation aerosol. The effect of flunisolide CFC inhalation aerosol and Flunisolide EG Inhalation Aerosol on pharmacokinetics and 12-hour plasma cortisol levels was investigated in two studies. In both studies, the Cmax and AUC of flunisolide, 6β-OH flunisolide, and 12-hour plasma cortisol measurements were comparable for 1000 mcg of flunisolide CFC inhalation aerosol and 320 mcg of Flunisolide EG Inhalation Aerosol. The first was a parallel arm study in 31 subjects. Pharmacokinetics and plasma cortisol levels were determined after single and multiple doses of flunisolide CFC inhalation aerosol 1000 μg and Flunisolide EG Inhalation Aerosol 160 μg or 320 μg administered twice daily for 13.5 days. At steady state, flunisolide mean peak plasma concentrations from flunisolide CFC inhalation aerosol 1000 mcg and Flunisolide EG Inhalation Aerosol 320 mcg were found to be 2.6 ng/mL and 3.4 ng/mL, respectively. The corresponding mean AUC values for the 12-hr dosing interval were 5.7 ng.hr/mL and 4.7 ng.hr/mL, respectively. At steady state, the mean peak plasma concentrations of 6β-OH flunisolide from flunisolide CFC inhalation aerosol 1000 mcg and Flunisolide EG Inhalation Aerosol 320 mcg were found to be 0.9 ng/mL and 0.3 ng/mL, respectively. The corresponding mean AUC values for the 12-hr dosing interval were 3.8 ng.hr/mL and 1.1 ng.hr/mL, respectively. The second was a crossover study in 11 subjects after single doses of flunisolide CFC inhalation aerosol 1000 mcg or Flunisolide EG Inhalation Aerosol 320 mcg. The mean peak plasma concentrations of flunisolide from the flunisolide CFC inhalation aerosol 1000 mcg and Flunisolide EG Inhalation Aerosol 320 mcg were found to be 2.5 ng/mL and 3.3 ng/mL, respectively. The corresponding mean AUC values were 5.1 ng.hr/mL and 5.8 ng.hr/mL, respectively. The mean peak plasma concentrations of 6 β -OH flunisolide from flunisolide CFC inhalation aerosol 1000 mcg and Flunisolide EG Inhalation Aerosol 320 mcg were found to be 0.8 ng/mL and 0.3 ng/mL, respectively. The corresponding mean AUC values were 3.8 ng.hr/mL and 2.3 ng.hr/mL, respectively.
Controlled clinical studies with flunisolide CFC inhalation aerosol included over 500 treated asthma patients, among them 150 children aged 6 years and older. Open label studies of two years or more duration included more than 120 treated patients. No significant adrenal suppression attributed to flunisolide was seen in these studies.
The potential effects of Flunisolide EG Inhalation Aerosol and flunisolide CFC inhalation aerosol on the hypothalamic-pituitary-adrenal (HPA) axis were studied in 2 placebo-and active-controlled studies and 2 active-controlled, open label, long-term studies [see Clinical Studies In the placebo-controlled studies, the ability to increase cortisol production in response to stress was assessed by the 60 minute cosyntropin (ACTH) stimulation test. For adult and adolescent patients treated with Flunisolide EG Inhalation Aerosol 80 mcg, 160 mcg, 320 mcg, or placebo twice daily for 12 weeks, 92% (22/24), 93% (26/28), 93% (26/28), and 92% (22/24) of patients, normal at baseline, respectively, continued to have a normal stimulated cortisol response (peak cortisol ≥ 18 mcg/dL and an increase in plasma cortisol ≥ 7 mcg/dL within 60 minutes after cosyntropin injection) at trial's end. All patients had peak cortisol levels ≥ 18mcg/dL. There was no significant suppression of 24 hour urinary cortisol, and 100% (96/96) of patients treated with Flunisolide EG Inhalation Aerosol had normal morning serum cortisol levels at the end of study. For pediatric patients treated with the Flunisolide EG Inhalation Aerosol, 80 mcg and 160 mcg or placebo twice daily for 12 weeks, 91% (31/34), 97% (28/29), and 89% (24/27) of patients, respectively, continued to have a normal stimulated cortisol response (as defined above) at trial's end. No suppression of 24-hour urinary cortisol was noted. In these studies, comparable results were obtained in patients treated with flunisolide CFC inhalation aerosol.
In the active-controlled, open label, long-term studies, 99.4% (161/162) of adult and adolescent patients and 98.4% (126/128) pediatric patients treated with Flunisolide EG Inhalation Aerosol had normal morning serum cortisol levels ( ≥ 5 mcg/dL) after 12 or 52 weeks of treatment, respectively. For patients treated with Flunisolide EG Inhalation Aerosol, 92.5% (99/107) continued to have a normal stimulated plasma cortisol response to cosyntropin at trial's end with all having peak cortisol levels ≥ 18mcg/dL. In these studies, no suppression of 24-hour urinary cortisol was noted, and comparable results were obtained in patients treated with flunisolide CFC inhalation aerosol.
All the data described below is based on studies conducted in subjects 18 to 51 years of age.
AbsorptionFlunisolide is rapidly absorbed after oral inhalation. Mean values for the time to maximum concentration, Tmax, of flunisolide range from 0.09 to 0.17 hr after a single 320 mcg dose of Flunisolide EG Inhalation Aerosol. The corresponding mean values for the maximum concentration, Cmax, of flunisolide vary from 1.9 to 3.3 ng/mL. Oral bioavailability is less than 7%. Over the dose range of 80 mcg to 320 mcg of Flunisolide EG Inhalation Aerosol, values for Cmax increase proportionately with dose after single as well as multiple dose administration.
DistributionFlunisolide is extensively distributed in the body, with mean values for apparent volume of distribution ranging from 170 to 350 L after a single 320 mcg dose of Flunisolide EG Inhalation Aerosol.
MetabolismFlunisolide is rapidly and extensively converted to 6ß-OH flunisolide and to water-soluble conjugates during the first pass through the liver. Conversion to 6ß-OH flunisolide, the only circulating metabolite detected in man, is thought to occur via the cytochrome P450 enzyme system, particularly the enzyme CYP3A4. 6ß-OH flunisolide has a low corticosteroid potency (ten times less potent than cortisol and more than 200 times less potent than flunisolide). Maximum levels of 6ß-OH flunisolide were 0.66 mcg/mL after a single 320 mcg dose of Flunisolide EG Inhalation Aerosol, and 0.71 mcg/mL after multiple doses of Flunisolide EG Inhalation Aerosol.
ExcretionUrinary excretion of flunisolide is low. Less than 1% of the administered dose of flunisolide is recovered in urine after inhalation. The half-life values for 6ß-OH flunisolide range from 3.1 to 5.1 hrs after administration of Flunisolide EG Inhalation Aerosol in the dose range of 160 mcg to 320 mcg.
Disposition and EliminationTwice daily inhalation administration of flunisolide for up to 14 days did not result in appreciable accumulation of flunisolide. Upon multiple dosing with 160 mcg and 320 mcg, the Cmax values were 1.0 ng/mL and 2.1 ng/mL, respectively. The corresponding AUC0-12hr values were 1.2 ng.hr/mL and 2.5 ng.hr/mL.
Flunisolide is rapidly cleared from the body, independent of route of administration or dose administered. Flunisolide is not detectable in plasma twelve hours post-dose. After administration of 320 mcg of Flunisolide EG Inhalation Aerosol the elimination half-life ranges from 1.3 to 1.7 hours. After a single 320 mcg dose, mean oral clearance values, not adjusted for bioavailability, range from 83 to 167 L/hr.
Included as part of the PRECAUTIONS section.
PRECAUTIONS Local InfectionsIn clinical studies with flunisolide, localized infections with Candida albicans or Aspergillus niger have occurred in the mouth and pharynx and occasionally in the larynx. If oropharyngeal candidiasis develops, treat with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with Flunisolide EG Inhalation Aerosol therapy, but at times therapy with Flunisolide EG Inhalation Aerosol may need to be temporarily interrupted under close medical supervision. Rinsing the mouth after inhalation is advised..
Acute Asthma EpisodesFlunisolide EG Inhalation Aerosol is not a bronchodilator and is not indicated for rapid relief of bronchospasm. Instruct patients to contact their physician immediately when episodes of asthma that are not responsive to bronchodilators occur during the course of treatment with Flunisolide EG Inhalation Aerosol. During such episodes, patients may require therapy with systemic corticosteroids.
ImmunosuppressionPatients who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and prior corticosteroid treatment to the risk is also not known. If a patient is exposed to chickenpox, prophylaxis with varicella-zoster immune globulin (VZIG) may be indicated. If a patient is exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chickenpox develops, treatment with antiviral agents may be considered.
Because of the potential for worsening infections, use inhaled corticosteroids with caution, if at all, in patients with untreated active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, parasitic or viral infections; or ocular herpes simplex.
Transfer from Systemic CorticosteroidsParticular care is needed in patients who are transferred from systemically active corticosteroids to Flunisolide EG Inhalation Aerosol because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function.
Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery or infections (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although Flunisolide EG Inhalation Aerosol may provide control of asthmatic symptoms during these episodes, in recommended doses it supplies less than the physiologic amounts of glucocorticoid (cortisol) systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies.
During periods of stress or a severe asthmatic attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume systemic steroids immediately and to contact their physician for further instruction. Instruct these patients to carry a warning card indicating that they may need supplementary systemic steroids during periods of stress or a severe asthma attack.
Wean patients requiring oral corticosteroids slowly from systemic corticosteroid use after transferring to Flunisolide EG Inhalation Aerosol. Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg/day on a weekly basis or morning peak expiratory flow rate [AM PEF]), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition to monitoring asthma signs and symptoms, observe patients for signs and symptoms of adrenal insufficiency such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.
Transfer of patients from systemic corticosteroid therapy to Flunisolide EG Inhalation Aerosol may unmask allergic conditions previously suppressed by the systemic corticosteroid therapy, e.g. rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions.
During withdrawal from oral corticosteroids, some patients may experience symptoms of systemically active corticosteroid withdrawal, e.g., joint or muscular pain, lassitude and depression, despite maintenance or even improvement of respiratory function.
Hypercorticism and Adrenal SuppressionIn responsive patients, flunisolide may permit control of asthmatic symptoms with less suppression of HPA axis function than therapeutically equivalent oral doses of prednisone. Since flunisolide is absorbed into the circulation and can be systemically active, the beneficial effects of Flunisolide EG Inhalation Aerosol in minimizing or preventing HPA axis dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing Flunisolide EG Inhalation Aerosol.
Because of the possibility of systemic absorption of inhaled corticosteroids, observe patients treated with Flunisolide EG Inhalation Aerosol carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients post-operatively or during periods of stress for evidence of inadequate adrenal response.
It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear in a small number of patients, particularly at higher doses. If such changes occur, reduce the Flunisolide EG Inhalation Aerosol dose slowly, consistent with accepted procedures for management of asthma symptoms and for tapering of systemic corticosteroids.
Reduction in Bone Mineral DensityDecreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids, including flunisolide. The clinical significance of small changes in BMD with regard to long-term outcomes is unknown. Monitor patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) and treat with established standards of care.
Effects on GrowthOrally inhaled corticosteroids, including flunisolide, may cause a reduction in growth velocity when administered to pediatric patients. Monitor the growth of children and adolescents receiving Flunisolide EG Inhalation Aerosol. To minimize the systemic effects of orally inhaled corticosteroids, including Flunisolide EG Inhalation Aerosol, each titrate each patient to his/her lowest effective dose.
Glaucoma and CataractsGlaucoma, increased intraocular pressure, and cataracts have been reported in patients following the long-term administration of inhaled corticosteroids, including flunisolide. Monitor patients closely, especially patients with a change in vision or with a history of increased intraocular pressure, glaucoma, or cataracts.
Paradoxical BronchospasmAs with other inhaled asthma medications, bronchospasm may occur with an immediate increase in wheezing after dosing. If bronchospasm occurs following dosing with Flunisolide EG Inhalation Aerosol, treat immediately with a fast-acting inhaled bronchodilator. Discontinue treatment with Flunisolide EG Inhalation Aerosol immediately and institute alternative therapy.
Patient Counseling InformationSee FDA-approved Patient Labeling (Patient Information and Instructions for Use).
Oral CandidiasisAdvise patients that localized fungal infections occurred in the mouth and pharynx in some patients. If oropharyngeal candidiasis develops, treat with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with Flunisolide EG Inhalation Aerosol therapy, but at times therapy with Flunisolide EG Inhalation Aerosol may need to be temporarily interrupted under close medical supervision. Rinsing the mouth after inhalation is advised.
Status Asthmaticus and Acute Asthma SymptomsAdvise patients that Flunisolide EG Inhalation Aerosol is not a bronchodilator and is not intended to be used to treat status asthmaticus or to relieve acute asthma symptoms. Treat acute asthma symptoms with an inhaled, short-acting beta-2 agonist such as albuterol. Instruct patients to contact their physicians immediately if there is deterioration of their asthma.
ImmunosuppressionWarn patients who are on immunosuppressant doses of Flunisolide EG Inhalation Aerosol to avoid exposure to chickenpox or measles and, if exposed, to consult their physician without delay. Inform patients of potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex.
Hypercorticism and Adrenal SupressionAdvise patients that Flunisolide EG Inhalation Aerosol may cause systemic corticosteroid effects of hypercorticism and adrenal suppression. Additionally, instruct patients that deaths due to adrenal insufficiency have occurred during and after transfer from systemic corticosteroids. Taper patients slowly from systemic corticosteroids if transferring to Flunisolide EG Inhalation Aerosol.
Reduction in Bone Mineral DensityAdvise patients who are at an increased risk for decreased BMD that the use of corticosteroids may pose an additional risk. Monitor patients and, where appropriate, treat for this condition.
Reduced Growth VelocityInform patients that orally inhaled corticosteroids, including Flunisolide EG Inhalation Aerosol, may cause a reduction in growth velocity when administered to pediatric patients. Physicians should closely follow the growth of children and adolescents taking corticosteroids by any route.
Ocular EffectsLong-term use of inhaled corticosteroids, including Flunisolide EG Inhalation Aerosol, may increase the risk of some eye problems (cataracts or glaucoma); consider regular eye examinations.
Use Daily for Best EffectAdvise patients to use Flunisolide EG Inhalation Aerosol at regular intervals as directed, since its effectiveness depends on regular use. Individual patients will experience a variable time to onset and degree of symptom relief, and the full benefit may not be achieved until treatment has been administered for 2 to 4 weeks. If symptoms do not improve in that time frame or if the condition worsens, patients should not increase dosage, but should contact the physician immediately.
Advise patients not to stop Flunisolide EG Inhalation Aerosol or change the dose without talking with a healthcare provider. Advise patients that if they miss a dose to take the next scheduled dose when it is due.
Instructions for UseFlunisolide EG Inhalation Aerosol contains a built-in spacer. Do not use with any external spacer or holding chamber devices. Instruct patients to prepare the inhaler for use by pulling the built-in purple actuator out from the gray spacer and snapping into an “L” shape prior to use. With use, the appearance of a white ring on the orifice of the actuator and inside the spacer is normal. The performance of Flunisolide EG Inhalation Aerosol is not affected by this residue. No cleaning is required.
Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment of FertilityIn a 22 month study in Swiss mice, flunisolide at oral doses up to 500 mcg/kg/day (approximately 3 and 4 times the maximum recommended daily inhalation dose [MRDID] in adults and children on a mg/m² basis) did not demonstrate any carcinogenic effects.
In a two year study in Sprague Dawley rats, administration of flunisolide in the diet at a dose of 2.5 mcg/kg/day (less than MRDID in adults or children on a mg/m² basis) resulted in an increased incidence of mammary gland adenomas and islet cell adenomas of the pancreas in females. The significance of these findings for humans is unknown. There were no significant increases in the incidence of any tumor type in female rats at a dose of 1.0 mcg/kg/day (less than MRDID in adults or children on a mg/m² basis), or in male rats at a dose of 2.5 mcg/kg/day (less than MRDID in adults or children on a mg/m² basis).
Flunisolide showed no mutagenic activity when tested in in vitro bacterial assay systems (Ames Assay and the Rec-assay) and no clastogenic activity when tested in the in vitro chromosomal aberration assay using Chinese Hamster CHL cells and in the in vivo mouse bone marrow chromosomal aberration assay.
Studies on the effects of flunisolide on fertility in female rats showed that flunisolide, at an oral dose of 200 mcg/kg/day (approximately 3 times MRDID on a mg/m² basis) impaired fertility, but was devoid of such effects at doses up to 40 mcg/kg/day (less than MRDID on a mg/m² basis).
Use In Specific Populations Pregnancy Pregnancy Category CThere are no adequate and well-controlled studies of flunisolide in pregnant women. Flunisolide EG Inhalation Aerosol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
As with other corticosteroids, flunisolide has been shown to be teratogenic and fetotoxic in rabbits and rats at approximately 1 and 3 times the maximum recommended daily inhalation dose on a mg/m² basis, respectively (doses of 40 and 200 mcg/kg/day, respectively).
Experience with oral corticosteroids since their introduction in pharmacologic, as opposed to physiological, doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans.
Nonteratogenic EffectsHypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully monitored.
Nursing MothersIt is not known whether flunisolide is excreted in human milk. Because other corticosteroids are excreted in human milk, caution should be exercised when Flunisolide EG Inhalation Aerosol is administered to nursing women.
Pediatric UseThe safety and effectiveness of Flunisolide EG Inhalation Aerosol has been studied in children 4-17 years of age. In clinical studies, the efficacy of Flunisolide EG Inhalation Aerosol was not established in children 4-5 years of age, although the adverse reaction profile observed in patients exposed to Flunisolide EG Inhalation Aerosol was similar between the 4-5 year age group (n=21), the 6-11 year age group (n=210), the 12-17 year age group (n=30), and those patients 18 years of age and older (n=258). The safety and effectiveness of Flunisolide EG Inhalation Aerosol has not been studied in patients less than 4 years of age.
Effects on GrowthControlled clinical studies have shown that orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients. In these studies, the mean reduction in growth velocity was approximately one cm per year (range 0.3 to 1.8 cm per year) and appears to depend upon the dose and duration of exposure. This effect was observed in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The long-term effects of this reduction in growth velocity associated with orally inhaled corticosteroids, including the impact on final adult height, are unknown. The potential for “catch up” growth following discontinuation of treatment with orally inhaled corticosteroids has not been adequately studied. The growth of pediatric patients receiving orally inhaled corticosteroids, including Flunisolide EG Inhalation Aerosol, should be monitored routinely (e.g., via stadiometry). The potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the risks/benefits of treatment alternatives. To minimize the systemic effects of orally inhaled corticosteroids, including Flunisolide EG Inhalation Aerosol, each patient should be titrated to the lowest dose that effectively controls his/her symptoms.
The potential effect of Flunisolide EG on growth rates in children was assessed in a 52 week randomized, placebo controlled study conducted in 242 prepubescent children age 4 to 9.5 years (145 males, 97 females) with mild persistent asthma. Treatment groups were Flunisolide EG 160 mcg twice daily and placebo. Growth velocity was estimated for each patient using the slope of the linear regression of height over time using observed data in the intent to treat population who had at least 3 height measurements. The mean growth velocities were 6.19 cm/year in the placebo group and 6.01 cm/year in the Flunisolide EG treated group (difference from placebo -0.17 cm/year; 95% CI: -0.58, 0.24).
Geriatric UseClinical studies of Flunisolide EG Inhalation Aerosol included 21 patients 65 to 78 years of age exposed to Flunisolide EG Inhalation Aerosol. These studies did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Flunisolide EG Inhalation Aerosol should be administered by the orally inhaled route in asthmatic patients aged 6 years and older. This product contains a built-in spacer. Do not use with any external spacer or holding chamber devices. Instruct patients to prepare the inhaler for use by pulling the built-in purple actuator out from the gray spacer and snapping into an “L” shape prior to use. Pediatric patients should administer this product under adult supervision.
The onset and degree of symptom relief with orally inhaled corticosteroids is usually apparent within 2-4 weeks after the start of treatment, and varies with individual patients. The time to improvement in asthma control was not evaluated in clinical studies with Flunisolide EG Inhalation Aerosol. For patients who do not respond adequately to the starting dose after 3-4 weeks of therapy, higher doses may provide additional asthma control. The safety and efficacy of Flunisolide EG Inhalation Aerosol when administered in excess of recommended doses have not been established.
The recommended starting dosage and the highest recommended dosage of Flunisolide EG Inhalation Aerosol are listed in Table 1.
Table 1: Recommended Doses of Flunisolide EG Inhalation Aerosol
Note: In all patients it is desirable to titrate to the lowest effective dose once asthma stability is achieved.
| Age Group | Recommended Starting Dose | Highest Recommended Dose |
| Adults and Adolescents 12 years of age and older† | 160 mcg twice daily | 320 mg twice daily* |
| Children 6 to 11 years† | 80 mcg twice daily | 160 mcg twice daily* |
| * Higher doses have not been studied. † For Patients Currently Receiving Chronic Oral Corticosteroid Therapy: Clinical studies with Flunisolide EG Inhalation Aerosol did not evaluate patients on oral corticosteroids. However, clinical studies with therapeutic doses of flunisolide CFC inhalation aerosol did show efficacy in the management of asthmatics dependent or maintained on systemic corticosteroids. Reduce the dose of prednisone no faster than 2.5 mg/day on a weekly basis, beginning after at least 1 week of therapy with Flunisolide EG. Monitor patients carefully for signs of asthma instability, including serial objective measures of airflow, and for signs of adrenal insufficiency during steroid taper and following discontinuation of oral corticosteroid therapy. |
